On August 3, 2026, it was reported that AstraZeneca and Bristol Myers Squibb (BMS), both valued over $130 billion, discussed a potential merger that, if successful, could reset the pharmaceutical deal-making environment. Despite speculation, analysts deemed the merger 'unlikely' due to significant product overlap leading to potential antitrust challenges. AstraZeneca's stock fell by over 4%, while BMS's rose nearly 6% following the news. Key overlaps in therapeutic areas, particularly in lung cancer treatments, could complicate merger approvals, with analysts pointing to previous BMS experience needing divestitures to finalize deals. If achieved, the merger could generate $100 billion in annual sales and establish the largest oncology portfolio, significantly affecting the cancer treatment landscape.

Show Search

Search Query Submit Search

‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever

August 3, 2026 |

3 min read |

Annalee Armstrong

3d poster image full pop art collage of human hand point wild fauna fish swim underwater natural habitat explore journey.

iStock, Deagreez

If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.

News broke over the weekend that Bristol Myers Squibb and AstraZeneca—both massive pharma companies worth more than $130 billion each—have held talks to merge. Analysts largely brushed off the idea as “unlikely,” given the companies have major competing products that would likely snarl the deal in antitrust review.

On Monday morning, AstraZeneca’s shares fell more than 4% in pre-market trading to $162.13. On the flip side, BMS rose nearly 6% to $69.20.

Rumors of such a deal were reported by The Financial Times on Sunday. If the mega-merger did come to pass, it would be the largest in the pharma industry’s history. But analysts are skeptical.

Largest Pharma deals Ever Redo Aug 2026

Use the column header buttons to sort columns by ascending or descending orderCurrently not sorted

Announced Date	Target	Buyer	Transaction Value	Closed Date
Announced Date<br>01/03/2019	Target<br>Celgene	Buyer<br>Bristol-Myers Squibb	Transaction Value<br>$99.6B	Closed Date<br>11/20/2019
Announced Date<br>06/25/2019	Target<br>Allergan	Buyer<br>AbbVie	Transaction Value<br>$86.2B	Closed Date<br>05/08/2020
Announced Date<br>02/08/2000	Target<br>Warner-Lambert	Buyer<br>Pfizer	Transaction Value<br>$85.6B	Closed Date<br>06/19/2000
Announced Date<br>04/19/2018	Target<br>Shire	Buyer<br>Takeda Pharmaceutical	Transaction Value<br>$80.9B	Closed Date<br>01/08/2019
Announced Date<br>01/17/2000	Target<br>SmithKline Beecham	Buyer<br>GSK	Transaction Value<br>$79.8B	Closed Date<br>12/27/2000
Announced Date<br>01/26/2009	Target<br>Wyeth	Buyer<br>Pfizer	Transaction Value<br>$79.6B	Closed Date<br>10/15/2009
Announced Date<br>11/17/2014	Target<br>Allergan	Buyer<br>Actavis	Transaction Value<br>$72.9B	Closed Date<br>03/17/2015
Announced Date<br>01/26/2004	Target<br>Aventis	Buyer<br>Sanofi	Transaction Value<br>$69.3B	Closed Date<br>08/30/2004
Announced Date<br>07/15/2002	Target<br>Pharmacia	Buyer<br>Pfizer	Transaction Value<br>$67.7B	Closed Date<br>04/16/2003
Announced Date<br>03/09/2009	Target<br>Schering-Plough	Buyer<br>Merck & Co.	Transaction Value<br>$51.4B	Closed Date<br>11/03/2009

Use the search bar to find a PRV

‹

/ 1

›

“Based on significant business overlap, we believe a deal is less likely to materialize,” BMO Capital Markets wrote on Sunday evening. The analysts pointed to the heavy scrutiny the deal would likely receive from antitrust officials on both sides of the pond.

“Looking across both Bristol and AstraZeneca’s commercial portfolio, we note several areas of overlap that could reduce the odds of a successful merger,” BMO said.

Most notably, the companies compete in non-small cell lung cancer with BMS’s Opdivo and AstraZeneca’s Imfinzi. Opdivo brought in $10.05 billion worldwide in 2025, while Imfinzi took in $6.06 billion.

“Multiple other therapeutic overlaps exist between the two companies to varying degrees of competition, likely raising FTC questions on potential anti-competitive issues with a deal,” BMO said.

BMS is no stranger to mega deals. The company bought Celgene in 2019 for $74 billion. To complete that deal, BMS was ordered to divest psoriasis and psoriatic arthritic drug Otezla to Amgen.

Deals

Bristol-Myers Squibb Plans to Sell Celgene’s Otezla in Attempt to Expedite Acquisition

“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”

June 24, 2019

2 min read

Mark Terry

Neither BMS nor AstraZeneca has the firepower to buy the other outright, BMO added, making a direct acquisition unlikely. The analysts put BMS’s deal capacity at about $32 billion and AstraZeneca’s around $37 billion. BMS has a current market cap of $133.41 billion, while AstraZeneca is larger at $195.93 billion, according to data from S&P Capital IQ.

If the deal does manage to overcome all the hurdles in front of it, analysts suspect the achievement could reset the current deal environment, which has already been busy in the first half of the year.

“A successful AZN-BMS merger could trigger a new wave of M&A among large global pharma companies,” Jefferies wrote on Sunday.

A new paradigm in cancer treatment

The joining of AstraZeneca and BMS would also reset the cancer landscape, Jefferies noted. The combined company would rake in $100 billion in annual sales with the “deepest oncology portfolio in the industry,” the firm wrote.

“The strategic rationale may be extending beyond cost synergies to a competition for larger portfolios of complementary assets that can support complex combination regimens,” Jefferies said.

Up until now, AstraZeneca has successfully combined its Imfinzi with the Daiichi Sankyo–partnered drug Enhertu and Datroway. Should BMS join AstraZeneca, it would open the door for Opdivo combos.

“A combination with BMS would remove the commercial barriers to exploring more combinations with Opdivo, which has a broader scientific and commercial footprint than Imfinzi,” Jefferies wrote.

The companies could also look at triplet regimens by pairing targeted therapies with immuno-oncology drugs and antibody-drug conjugates (ADCs). AstraZeneca has many of these targeted options in its portfolio, including Tagrisso, Lynparza, Truqap and the investigational camizestrant, which is under FDA review. BMS, meanwhile, has immuno-oncology asset Yervoy and next-generation programs in the clinic, Jefferies said.

Working together, BMS and AstraZeneca could create complex treatment regimens in lung, breast, ovarian and gastrointestinal cancers, Jefferies said.

“Combination therapies increasingly define the standard of care in oncology, and the ability to develop and commercialize more complex multi-drug regimens without cross-company negotiations may ultimately prove one of the most compelling strategic rationales for a merger.”

Earnings

AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure

AstraZeneca remains “very much on track” to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said during the company’s Q2 earnings presentation on Monday.

July 27, 2026

3 min read

Tristan Manalac

Mergers & acquisitions Breast cancer Antibody-drug conjugate (ADC)

AstraZeneca Bristol Myers Squibb Company

Annalee Armstrong

Annalee Armstrong is senior editor at BioSpace. You can reach her at  annalee.armstrong@biospace.com. Follow her on LinkedIn.